Long-term corticosteroid treatment of myasthenia gravis: Report of 116 patients

Robert Pascuzzi, H. Branch Coslett, T. R. Johns

Research output: Contribution to journalArticle

226 Citations (Scopus)

Abstract

One hundred sixteen patients, aged 8 to 82 years, with myasthenia gravis were treated with prednisone, 60 to 80 mg daily, until the onset of improvement, followed by lower-dose alternate-day therapy of several years' duration. Of all patients, 80.2% achieved either remission (27.6%) or marked improvement (52.6%). Moderate improvement occurred in 14.7%, and 5.2% showed no improvement. Increasing age correlated with a favorable outcome, but sex, duration of illness prior to treatment, severity and distribution of weakness at the time of onset of treatment, and presence of thymoma were not factors in the response to therapy.

Original languageEnglish (US)
Pages (from-to)291-298
Number of pages8
JournalAnnals of Neurology
Volume15
Issue number3
StatePublished - 1984
Externally publishedYes

Fingerprint

Myasthenia Gravis
Adrenal Cortex Hormones
Thymoma
Therapeutics
Prednisone

ASJC Scopus subject areas

  • Neuroscience(all)

Cite this

Long-term corticosteroid treatment of myasthenia gravis : Report of 116 patients. / Pascuzzi, Robert; Branch Coslett, H.; Johns, T. R.

In: Annals of Neurology, Vol. 15, No. 3, 1984, p. 291-298.

Research output: Contribution to journalArticle

Pascuzzi, Robert ; Branch Coslett, H. ; Johns, T. R. / Long-term corticosteroid treatment of myasthenia gravis : Report of 116 patients. In: Annals of Neurology. 1984 ; Vol. 15, No. 3. pp. 291-298.
@article{3d1238636bb249e1b667ba1318bd6db8,
title = "Long-term corticosteroid treatment of myasthenia gravis: Report of 116 patients",
abstract = "One hundred sixteen patients, aged 8 to 82 years, with myasthenia gravis were treated with prednisone, 60 to 80 mg daily, until the onset of improvement, followed by lower-dose alternate-day therapy of several years' duration. Of all patients, 80.2{\%} achieved either remission (27.6{\%}) or marked improvement (52.6{\%}). Moderate improvement occurred in 14.7{\%}, and 5.2{\%} showed no improvement. Increasing age correlated with a favorable outcome, but sex, duration of illness prior to treatment, severity and distribution of weakness at the time of onset of treatment, and presence of thymoma were not factors in the response to therapy.",
author = "Robert Pascuzzi and {Branch Coslett}, H. and Johns, {T. R.}",
year = "1984",
language = "English (US)",
volume = "15",
pages = "291--298",
journal = "Annals of Neurology",
issn = "0364-5134",
publisher = "John Wiley and Sons Inc.",
number = "3",

}

TY - JOUR

T1 - Long-term corticosteroid treatment of myasthenia gravis

T2 - Report of 116 patients

AU - Pascuzzi, Robert

AU - Branch Coslett, H.

AU - Johns, T. R.

PY - 1984

Y1 - 1984

N2 - One hundred sixteen patients, aged 8 to 82 years, with myasthenia gravis were treated with prednisone, 60 to 80 mg daily, until the onset of improvement, followed by lower-dose alternate-day therapy of several years' duration. Of all patients, 80.2% achieved either remission (27.6%) or marked improvement (52.6%). Moderate improvement occurred in 14.7%, and 5.2% showed no improvement. Increasing age correlated with a favorable outcome, but sex, duration of illness prior to treatment, severity and distribution of weakness at the time of onset of treatment, and presence of thymoma were not factors in the response to therapy.

AB - One hundred sixteen patients, aged 8 to 82 years, with myasthenia gravis were treated with prednisone, 60 to 80 mg daily, until the onset of improvement, followed by lower-dose alternate-day therapy of several years' duration. Of all patients, 80.2% achieved either remission (27.6%) or marked improvement (52.6%). Moderate improvement occurred in 14.7%, and 5.2% showed no improvement. Increasing age correlated with a favorable outcome, but sex, duration of illness prior to treatment, severity and distribution of weakness at the time of onset of treatment, and presence of thymoma were not factors in the response to therapy.

UR - http://www.scopus.com/inward/record.url?scp=0021329141&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0021329141&partnerID=8YFLogxK

M3 - Article

C2 - 6721451

AN - SCOPUS:0021329141

VL - 15

SP - 291

EP - 298

JO - Annals of Neurology

JF - Annals of Neurology

SN - 0364-5134

IS - 3

ER -